T3DB: Salvinorin A

Identification Taxonomy Biological Properties Physical Properties Toxicity Profile Spectra Concentrations Links References Gene Regulation Targets (3)XML

Targets (3)

Record Information

Version

2.0

Creation Date

2009-07-30 17:59:08 UTC

Update Date

2014-12-24 20:26:07 UTC

Accession Number

T3D3532

Identification

Common Name

Salvinorin A

Class

Small Molecule

Description

Salvinorin A is the main active psychotropic molecule in Salvia divinorum, a Mexican plant which has a long history of use as an entheogen by indigenous Mazatec shamans. Salvinorin A is a hallucinogenic compound with dissociative effects (10).

Compound Type

Ester
Ether
Natural Compound
Organic Compound
Plant Toxin

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Synonym
Diviner's sage
Divinorin a
Herbal ecstasy
Mexican mint
Salvinorin
Salvinorin a
Ska maria pastora

Chemical Formula

C₂₃H₂₈O₈

Average Molecular Mass

432.464 g/mol

Monoisotopic Mass

432.178 g/mol

CAS Registry Number

83729-01-5

IUPAC Name

methyl 9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-naphtho[2,1-c]pyran-7-carboxylate

Traditional Name

methyl 9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-octahydro-1H-naphtho[2,1-c]pyran-7-carboxylate

SMILES

COC(=O)C1CC(OC(C)=O)C(=O)C2C1(C)CCC1C(=O)OC(CC21C)C1=COC=C1

InChI Identifier

InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3

InChI Key

InChIKey=OBSYBRPAKCASQB-UHFFFAOYSA-N

Chemical Taxonomy

Description

belongs to the class of organic compounds known as diterpene lactones. These are diterpenoids containing a lactone moiety.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Prenol lipids

Sub Class

Terpene lactones

Direct Parent

Diterpene lactones

Alternative Parents

Substituents

Diterpene lactone
Diterpenoid
Clerodane diterpenoid
Naphthopyran
Naphthalene
Tricarboxylic acid or derivatives
Delta valerolactone
Delta_valerolactone
Alpha-acyloxy ketone
Pyran
Oxane
Methyl ester
Furan
Heteroaromatic compound
Carboxylic acid ester
Ketone
Lactone
Organoheterocyclic compound
Carboxylic acid derivative
Oxacycle
Organooxygen compound
Organic oxide
Organic oxygen compound
Carbonyl group
Hydrocarbon derivative
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Pathways

Not Available

Applications

Not Available

Biological Roles

Not Available

Chemical Roles

Not Available

Physical Properties

State

Solid

Appearance

Colorless crystals from methanol (2).

Experimental Properties

Property	Value
Melting Point	238-244°C
Boiling Point	Not Available
Solubility	Not Available
LogP	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.08 g/L	ALOGPS
logP	2.48	ALOGPS
logP	2.39	ChemAxon
logS	-3.7	ALOGPS
pKa (Strongest Acidic)	16.45	ChemAxon
pKa (Strongest Basic)	-3.2	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	109.11 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	106 m³·mol⁻¹	ChemAxon
Polarizability	44.23 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	splash10-006x-5079300000-0c3d81b169f1ec02eb08	2021-09-23	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	Not Available	2021-10-12	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	Not Available	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	splash10-001i-1008900000-3dde4855bc69f27483e4	2016-08-01	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	splash10-0gi3-1019500000-0d06ceb5fd22972dfc1e	2016-08-01	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	splash10-0gxw-3249100000-797004a599225d2018a4	2016-08-01	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	splash10-001r-3009600000-a9c68bc515eddd483f7d	2016-08-03	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	splash10-0a5i-3009200000-0bf80f4121126284c9d4	2016-08-03	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	splash10-0a4i-9006000000-f6147bd53d5e352b972c	2016-08-03	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	splash10-00di-0009200000-3c86e6f8f5d793dd7a0b	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	splash10-001i-0019100000-511b0cc4a7bbe7ac17a2	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	splash10-0002-9057100000-1307ddb5b9baf63a568b	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	splash10-0a4i-9000200000-4490b6cd9718932fc15b	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	splash10-0a4i-9002000000-18739f0784b8f7ec39da	2021-10-12	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	splash10-0a6v-9036300000-46b86aa451b8356c46c8	2021-10-12	View Spectrum

Toxicity Profile

Route of Exposure

Ingestion (11) ; dermal (11)

Mechanism of Toxicity

Salvinorin A, the active component of the hallucinogenic sage Salvia divinorum, is an apparently selective and highly potent kappa-opioid receptor (KOR) agonist. Salvinorin A is unique among ligands for peptidergic G protein-coupled receptors in being nonnitrogenous and lipid-like in character (3).

Metabolism

Salvinorin A’s chemical structure suggests that it may be a substrate of CYP450 (oxidative metabolism), UGT (hydrolysis) or carboxylesterases (ChEs) (hydrolysis). In addition, as observed for CYP1A1, CPY2C18 and CYP2E1, Salvinorin A metabolism via UGTB27 appears to be saturable at higher concentrations.

Toxicity Values

Not Available

Lethal Dose

Not Available

Carcinogenicity (IARC Classification)

No indication of carcinogenicity (not listed by IARC). (12)

Uses/Sources

Traditional medicine used by the Mazatec people of Oaxaca, Mexico (2).

Minimum Risk Level

Not Available

Health Effects

Psychedelic-like changes in visual perception, mood, and body sensations (4).

Symptoms

Hallucinations or delusional episodes that mimic psychosis. ; emotional swings; feelings of detachment; and importantly, a highly modified perception of external reality and the self, which leads to a decreased ability to interact with one's surroundings (4).

Treatment

Treatment for salvinorin A overdose would be similar to the treatments for hallucinogen intoxication. (5)

Normal Concentrations

Not Available

Abnormal Concentrations

Not Available

External Links

DrugBank ID

Not Available

HMDB ID

Not Available

PubChem Compound ID

128563

ChEMBL ID

Not Available

ChemSpider ID

Not Available

KEGG ID

Not Available

UniProt ID

Not Available

OMIM ID

ChEBI ID

Not Available

BioCyc ID

Not Available

CTD ID

Not Available

Stitch ID

Salvinorin A

PDB ID

Not Available

ACToR ID

Not Available

Wikipedia Link

Salvinorin

References

Synthesis Reference

Not Available

MSDS

T3D3532.pdf

General References

Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, Eddington ND: Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009 Jun;72(2):471-7. doi: 10.1016/j.ejpb.2009.01.002. [19462483 ]
McAlister ED, Van Vugt DA: Effect of leptin administration versus re-feeding on hypothalamic neuropeptide gene expression in fasted male rats. Can J Physiol Pharmacol. 2004 Dec;82(12):1128-34. [15644956 ]
Muhlhausler BS, Adam CL, Marrocco EM, Findlay PA, Roberts CT, McFarlane JR, Kauter KG, McMillen IC: Impact of glucose infusion on the structural and functional characteristics of adipose tissue and on hypothalamic gene expression for appetite regulatory neuropeptides in the sheep fetus during late gestation. J Physiol. 2005 May 15;565(Pt 1):185-95. Epub 2005 Jan 20. [15661821 ]
Loos RJ, Rankinen T, Tremblay A, Perusse L, Chagnon Y, Bouchard C: Melanocortin-4 receptor gene and physical activity in the Quebec Family Study. Int J Obes (Lond). 2005 Apr;29(4):420-8. [15597110 ]
Scruggs P, Lai CC, Scruggs JE, Dun NJ: Cocaine- and amphetamine-regulated transcript peptide potentiates spinal glutamatergic sympathoexcitation in anesthetized rats. Regul Pept. 2005 Apr 15;127(1-3):79-85. [15680473 ]
National Institute on Drug Abuse (NIDA) (2007). Infofacts: Salvia.
O'Neil MJ (ed) (2006). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th ed. Whitehouse Station, NJ: Merck and Co., Inc.
Vortherms TA et al; J Biol Chem 282 (5): 3146-56 (2007).
Biller J (2007). The Interface of Neurology & Internal Medicine. Philadelphia, PA: Wolters Kluwer Health, Lippincott/Williams and Wilkins.
Wikipedia. Salvinorin. Last Updated 8 August 2009. [Link]
Wikipedia. Phytotoxin. Last Updated 7 August 2009. [Link]
International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. [Link]

Gene Regulation

Up-Regulated Genes

Not Available

Down-Regulated Genes

Not Available

Targets

Target Details

1. Kappa-type opioid receptor

General Function:: Opioid receptor activity
Specific Function:: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
Gene Name:: OPRK1
Uniprot ID:: P41145
Molecular Weight:: 42644.665 Da

Binding/Activity Constants

Type	Value	Assay Type	Assay Source
Inhibitory	0.00075 uM	Not Available	BindingDB 50159165
Inhibitory	0.0008 uM	Not Available	BindingDB 50159165
Inhibitory	0.0013 uM	Not Available	BindingDB 50159165
Inhibitory	0.0019 uM	Not Available	BindingDB 50159165
Inhibitory	0.0024 uM	Not Available	BindingDB 50159165
Inhibitory	0.0025 uM	Not Available	BindingDB 50159165
Inhibitory	0.0026 uM	Not Available	BindingDB 50159165
Inhibitory	0.003 uM	Not Available	BindingDB 50159165
Inhibitory	0.0057 uM	Not Available	BindingDB 50159165
Inhibitory	0.0074 uM	Not Available	BindingDB 50159165

References

Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE: Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2. [18380425 ]
Fichna J, Lewellyn K, Yan F, Roth BL, Zjawiony JK: Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids. Bioorg Med Chem Lett. 2011 Jan 1;21(1):160-3. doi: 10.1016/j.bmcl.2010.11.046. Epub 2010 Nov 11. [21115248 ]
Ghirmai S, Azar MR, Cashman JR: Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. Bioorg Med Chem. 2009 Sep 15;17(18):6671-81. doi: 10.1016/j.bmc.2009.07.069. Epub 2009 Aug 6. [19683449 ]
Beguin C, Richards MR, Li JG, Wang Y, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM: Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85. Epub 2006 Jun 13. [16777411 ]
Lee DY, He M, Liu-Chen LY, Wang Y, Li JG, Xu W, Ma Z, Carlezon WA Jr, Cohen B: Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5498-502. Epub 2006 Aug 30. [16945525 ]
Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE: Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem. 2005 Jul 28;48(15):4765-71. [16033256 ]
Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P, Dersch CM, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE: Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod. 2006 Jun;69(6):914-8. [16792410 ]
Yamaotsu N, Fujii H, Nagase H, Hirono S: Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists. Bioorg Med Chem. 2010 Jun 15;18(12):4446-52. doi: 10.1016/j.bmc.2010.04.069. Epub 2010 Apr 28. [20478711 ]
Munro TA, Duncan KK, Xu W, Wang Y, Liu-Chen LY, Carlezon WA Jr, Cohen BM, Beguin C: Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. Epub 2007 Oct 24. [17981041 ]
Beguin C, Duncan KK, Munro TA, Ho DM, Xu W, Liu-Chen LY, Carlezon WA Jr, Cohen BM: Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem. 2009 Feb 1;17(3):1370-80. doi: 10.1016/j.bmc.2008.12.012. Epub 2008 Dec 14. [19147366 ]
Beguin C, Potuzak J, Xu W, Liu-Chen LY, Streicher JM, Groer CE, Bohn LM, Carlezon WA Jr, Cohen BM: Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1023-6. doi: 10.1016/j.bmcl.2011.11.128. Epub 2011 Dec 7. [22204910 ]
Lozama A, Cunningham CW, Caspers MJ, Douglas JT, Dersch CM, Rothman RB, Prisinzano TE: Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A. J Nat Prod. 2011 Apr 25;74(4):718-26. doi: 10.1021/np1007872. Epub 2011 Feb 21. [21338114 ]
Lovell KM, Vasiljevik T, Araya JJ, Lozama A, Prevatt-Smith KM, Day VW, Dersch CM, Rothman RB, Butelman ER, Kreek MJ, Prisinzano TE: Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorg Med Chem. 2012 May 1;20(9):3100-10. doi: 10.1016/j.bmc.2012.02.040. Epub 2012 Mar 1. [22464684 ]

Target Details

2. Mu-type opioid receptor

General Function:: Voltage-gated calcium channel activity
Specific Function:: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.
Gene Name:: OPRM1
Uniprot ID:: P35372
Molecular Weight:: 44778.855 Da

Binding/Activity Constants

Type	Value	Assay Type	Assay Source
Inhibitory	1.37 uM	Not Available	BindingDB 50159165
Inhibitory	4.37 uM	Not Available	BindingDB 50159165
Inhibitory	>1 uM	Not Available	BindingDB 50159165
Inhibitory	>10 uM	Not Available	BindingDB 50159165

References

Lovell KM, Vasiljevik T, Araya JJ, Lozama A, Prevatt-Smith KM, Day VW, Dersch CM, Rothman RB, Butelman ER, Kreek MJ, Prisinzano TE: Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorg Med Chem. 2012 May 1;20(9):3100-10. doi: 10.1016/j.bmc.2012.02.040. Epub 2012 Mar 1. [22464684 ]
Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE: Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. doi: 10.1021/jm701162g. Epub 2008 Apr 2. [18380425 ]
Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE: Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem. 2005 Jul 28;48(15):4765-71. [16033256 ]
Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P, Dersch CM, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE: Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod. 2006 Jun;69(6):914-8. [16792410 ]
Fichna J, Lewellyn K, Yan F, Roth BL, Zjawiony JK: Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids. Bioorg Med Chem Lett. 2011 Jan 1;21(1):160-3. doi: 10.1016/j.bmcl.2010.11.046. Epub 2010 Nov 11. [21115248 ]

Target Details

3. Delta-type opioid receptor

General Function:: Opioid receptor activity
Specific Function:: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
Gene Name:: OPRD1
Uniprot ID:: P41143
Molecular Weight:: 40368.235 Da

Binding/Activity Constants

Type	Value	Assay Type	Assay Source
Inhibitory	>10 uM	Not Available	BindingDB 50159165

References

Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB: Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11934-9. Epub 2002 Aug 21. [12192085 ]

Salvinorin A (T3D3532)

Structure for T3D3532: Salvinorin A

Targets

Binding/Activity Constants

References

Binding/Activity Constants

References

Binding/Activity Constants

References